Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Issues
2023
April 2023, Vol 13, No 4
April 2023, Vol 13, No 4
Corporate Disrupters Are Moving Rapidly into Healthcare. Are We Watching?
By
Dawn Holcombe, MBA, FACMPE, ACHE
From the Editor
Big business has been investing billions of dollars per year into healthcare, and, if successful, it may make private practices and community hospitals anachronistic.
Read More ›
Experts Discuss Strategies for Achieving Health Equity in Bladder Cancer Care
By
William King
Disparities in Cancer Care
,
ASCO GU 2023 Highlights
,
Bladder Cancer
During the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, a panel of experts identified some of the key challenges to achieving health equity in bladder cancer care and discussed what can be done to improve access to clinical trials, mitigate financial toxicity, and promote value-based care.
Read More ›
ACS Reports Concerning Shift in Colorectal Cancer to Advanced Stage, Younger Age at Diagnosis
By
Anne Rowe
Colorectal Cancer
A new report released by the American Cancer Society (ACS) shows that the incidence of colorectal cancer is rapidly increasing among younger individuals, and the disease is also being diagnosed at more advanced stages in people of all ages.
Read More ›
Study Probes Awareness of Alcohol’s Link to Cancer
By
Anna Hopkins
Patient Advocacy
Numerous changes need to be made to raise public awareness of the fact that drinking alcohol raises the risk for several types of cancer. That is a key conclusion from a new study conducted by a National Cancer Institute research team.
Read More ›
FDA Updates Mammography Regulations with Breast Density Notification Requirement
Healthcare Policy
,
Breast Cancer
The FDA has updated its mammography regulations to require reporting of breast density information by facilities, according to a statement by the organization on March 9, 2023.
Read More ›
Cybersecurity Framework Implementation Guide Helps Healthcare Organizations Manage Risk
Cybersecurity
The Health Sector Coordinating Council Cybersecurity Working Group and the US Department of Health and Human Services jointly released a guide to help the public and private healthcare sectors align their cybersecurity programs with the National Institute of Standards Technology Cybersecurity Framework.
Read More ›
Zynyz Receives FDA Accelerated Approval for Merkel-Cell Carcinoma
FDA Approvals, News & Updates
,
Skin Cancer
On
March 22, 2023
, the FDA granted accelerated approval to retifanlimab-dlwr (Zynyz; Incyte Corporation), a programmed cell death 1–blocking antibody, for the treatment of adult patients with metastatic or recurrent locally advanced Merkel-cell carcinoma.
Read More ›
Tafinlar plus Mekinist Combination Approved for Pediatric Low-Grade Glioma with BRAFV600E Mutation
FDA Approvals, News & Updates
,
Pediatric Cancers
,
Head & Neck Cancers
On
March 16, 2023
, the FDA approved dabrafenib (Tafinlar; Novartis) in combination with trametinib (Mekinist; Novartis) for the treatment of pediatric patients aged ≥1 year with low-grade glioma that harbors a
BRAF
V600E
mutation and who require systemic therapy.
Read More ›
FDA Expands Indication for Verzenio as Adjuvant Treatment for HR-Positive, HER2-Negative, Early Breast Cancer
FDA Approvals, News & Updates
,
Breast Cancer
On
March 3, 2023
, the FDA approved abemaciclib (Verzenio; Eli Lilly) plus endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor–positive,
HER2
-negative, node-positive, early breast cancer at high risk for recurrence.
Read More ›
Jemperli Receives Regular FDA Approval for Advanced Endometrial Cancer
FDA Approvals, News & Updates
,
Gynecologic Cancers
On
February 9, 2023
, the FDA approved dostarlimab-gxly (Jemperli; GlaxoSmithKline) for the treatment of adult patients with mismatch repair-deficient, recurrent or advanced endometrial cancer, as determined by an FDA-approved test, whose disease has progressed on or following a previous platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.
Read More ›
Page 1 of 2
1
2
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Molecular Characteristics Increasingly Define Adult Gliomas
By
William King
2.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
By
William King
3.
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
By
William King
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes